


I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on June 8, 2007

PATENT

Attorney Docket No.: 014740-001020US
Client Reference No.: TSRI 1007.1/NOV0616P

TOWNSEND and TOWNSEND and CREW LLP

By: 
Corinna Joss

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shuibing, Chen et al.

Confirmation No.: 4061

Application No.: 10/577,191

Examiner:

Filed: April 24, 2006

Art Unit: 1626

For: COMPOSITIONS AND METHODS
FOR INDUCING CELL
DEDIFFERENTIATION

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references can be found in the file for related application number 10/985,645, and accordingly are not enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue there from.

Also enclosed are copies of the Search report corresponding to the PCT application (Application No. PCT/US04/37686) and Search report corresponding to the European Search Report (Application No. 04 80 0997).

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Application No.: 10/577,191
Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Carol A. Fang', with a large, stylized loop at the end.

Carol A. Fang
Reg. No. 48,631

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
CAF:jkn
61057964 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/577,191
				Filing Date	April 24, 2006
				First Named Inventor	Shuibing, Chen et al.
				Art Unit	1626
Examiner Name					
Attorney Docket Number	014740-001020US				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2002/0016329 A1	02-07-2002	Imbach, et al.	
	2	2003/0225278 A1	12-04-2003	Ciszewski, et al.	
	3	5,924,225	08-24-1999	Bruder, et al.	
	4	6,255,485	07-03-2001	Gray, et al.	
	5	6,369,029	04-09-2008	Andress, et al.	
	6	6,589,950 B1	07-08-2003	Collingwood, et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	7	FR	2793794	A1	11-24-2000	HOECHST MARION ROUSSEL		
	8	WO	02/051843	A1	07-04-2002	AVENTIS PHARMA S.A.		
	9	WO	2005/047524	A2	05-26-2005	THE SCRIPPS RESEARCH INSTITUTE		
	10	WO	00/71543	A1	11-2000	HOECHST MARION ROUSSEL		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

61057964 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/577,191
				Filing Date	April 24, 2006
				First Named Inventor	Shuibing, Chen et al.
				Art Unit	1626
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	014740-001020US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	11	BASYOUNI, W.M., et al., "Synthesis and Antimicrobial Activity of Some New 6-Substituted 9-Arylpurine Derivatives," Egyptian J. Chem., 1999, Vol. 42, No. 6, pp. 587-598		
	12	CHEN, Shuibing, et al., "Dedifferentiation of Lineage-Committed Cells by a Small Molecule," J. AM. Chem. Soc., 2004, Vol. 126, pp 410-411.	<input type="checkbox"/>	
	13	GEY, Claudia, et al., "Small Molecules, Big Plans—Can Low-Molecular-Weight Compounds Control Human Regeneration?" Angew. Chem. Int. Ed., 2004, Vol. 43, No. 31, pp 3998-4000.	<input type="checkbox"/>	
	14	HILDEBRAND, Catherine, et al., "Structure-Activity Relationships of N ² -Substituted Guanines as Inhibitors of HSV1 and HSV2 Thymidine Kinases," J. Med. Chem., 1990, Vol. 33, pp 203-206.	<input type="checkbox"/>	
	15	IMBACH, P., et al., "2,6,9-Trisubstituted Purines: Optimization Towards Highly Potent and Selective CDK1 Inhibitors," Bioorganic & Medicinal Chemistry Letters, 1999, Vol. 9, pp. 91-96.		
	16	KELLEY, J., et al., "Antirhinovirus Activity of 6-Anilino-9-benzyl-2-chloro-9H-purines," J. Med. Chem., 1990, Vol. 33, pp. 1360-1363.		
	17	MEDVECZKY, Maria, et al., "Haloanilino Derivatives of Pyrimidines, Purines, and Purine Nucleoside Analogs: Synthesis and Activity against Human Cytomegalovirus," J. Med. Chem. 1995, Vol. 38, pp 1811-1819.	<input type="checkbox"/>	
	18	MONTGOMERY, J., et al., "Synthesis of Potential Anticancer Agents. XXVI. The Alkylation of 6-Chloropurine," February 5, 1961, Vol. 83, pp. 630-635.		
	19	WRIGHT, George E., et al., "Synthesis, Cell Growth Inhibition, and Antitumor Screening of 2-(p-n-Butylanilino) purines and Their Nucleoside Analogues," J. Med. Chem. 1987, Vol. 30, pp 109-116.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.